Yu Binglan, Volpato Gian Paolo, Chang Keqin, Bloch Kenneth D, Zapol Warren M
Anesthesia Center for Critical Care Research, Department of Anesthesia and Critical Care, Harvard Medical School at Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Anesthesiology. 2009 Jan;110(1):113-22. doi: 10.1097/ALN.0b013e318190bc4f.
Hemoglobin-based oxygen-carrying solutions (HBOC) provide emergency alternatives to blood transfusion to carry oxygen to tissues without the risks of disease transmission or transfusion reaction. Two primary concerns hampering the clinical acceptance of acellular HBOC are the occurrence of systemic and pulmonary vasoconstriction and the maintenance of the heme-iron in the reduced state (Fe2+). We recently demonstrated that pretreatment with inhaled nitric oxide prevents the systemic hypertension induced by HBOC-201 (polymerized bovine hemoglobin) infusion in awake mice and sheep without causing methemoglobinemia. However, the impact of HBOC-201 infusion with or without inhaled nitric oxide on pulmonary vascular tone has not yet been examined.
The pulmonary and systemic hemodynamic effects of breathing nitric oxide both before and after the administration of HBOC-201 were determined in healthy, awake lambs.
Intravenous administration of HBOC-201 (12 ml/kg) induced prolonged systemic and pulmonary vasoconstriction. Pretreatment with inhaled nitric oxide (80 parts per million [ppm] for 1 h) prevented the HBOC-201--induced increase in mean arterial pressure but not the increase of pulmonary arterial pressure, systemic vascular resistance, or pulmonary vascular resistance. Pretreatment with inhaled nitric oxide (80 ppm for 1 h) followed by breathing a lower concentration of nitric oxide (5 ppm) during and after HBOC-201 infusion prevented systemic and pulmonary vasoconstriction without increasing methemoglobin levels.
These findings demonstrate that pretreatment with inhaled nitric oxide followed by breathing a lower concentration of the gas during and after administration of HBOC-201 may enable administration of an acellular hemoglobin substitute without vasoconstriction while preserving its oxygen-carrying capacity.
基于血红蛋白的携氧溶液(HBOC)为输血提供了紧急替代方案,可将氧气输送到组织,而无疾病传播或输血反应风险。阻碍脱细胞HBOC临床应用的两个主要问题是全身和肺血管收缩的发生以及血红素铁维持在还原状态(Fe2+)。我们最近证明,吸入一氧化氮预处理可预防清醒小鼠和绵羊中由输注HBOC-201(聚合牛血红蛋白)引起的系统性高血压,且不会导致高铁血红蛋白血症。然而,输注HBOC-201(无论有无吸入一氧化氮)对肺血管张力的影响尚未得到研究。
在健康、清醒的羔羊中,测定输注HBOC-201前后呼吸一氧化氮时的肺和全身血流动力学效应。
静脉注射HBOC-201(12 ml/kg)可引起长时间的全身和肺血管收缩。吸入一氧化氮预处理(80 ppm,持续1小时)可预防HBOC-201引起的平均动脉压升高,但不能预防肺动脉压、全身血管阻力或肺血管阻力升高。吸入一氧化氮预处理(80 ppm,持续1小时),然后在输注HBOC-201期间及之后呼吸较低浓度的一氧化氮(5 ppm),可预防全身和肺血管收缩,且不会增加高铁血红蛋白水平。
这些发现表明,吸入一氧化氮预处理,然后在输注HBOC-201期间及之后呼吸较低浓度的一氧化氮,可能使无细胞血红蛋白替代物在不发生血管收缩的情况下给药,同时保留其携氧能力。